|
To support its discovery and clinical development activities of novel LNA drugs, Santaris Pharma A/S has invested heavily in its drug discovery and development capabilities, bringing together scientists with experience, talent and commitment to change the field of RNA-medicines. As a result the Company now controls a Drug Discovery Engine, which can rationally design and discover potent and safe RNA-targeted drugs, quickly and cost-effectively exploiting the efficiencies of the antisense technology. It is clear that further scale-up to support large clinical trials will allow oligonucleotide drugs to be produced at prices competitive with many other advanced therapies. |